Crestor, containing rosuvastatin, is a widely prescribed medication for the management of high blood cholesterol levels. It belongs to a class of drugs known as Cholesterol Medications and contains a combination of two active ingredients: rosuvastatin and calcium. Crestor works by blocking the action of a chemical called Statid in cholesterol cells, thereby reducing cholesterol levels. This mechanism of action increases the risk of cardiovascular complications associated with cholesterol-related diseases, such as heart attacks and strokes. Additionally, Crestor is not recommended for the management of type 2 diabetes. Increased blood pressure is believed to be a contributing factor to the increased risk of heart disease and stroke. Therefore, it is important to identify individuals at risk and develop appropriate treatment options.
The global cholesterol market was valued at USD 3.34 billion in 2023 and is anticipated to grow to USD 5.60 billion in 2030. As of 2023, the market size was valued at USD 4.60 billion and is expected to reach USD 6.90 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 4.26% from 2024 to 2031. The market is growing at a CAGR of 5.56% from 2024 to 2031, reaching a size C=5.61% in 2031).
North America holds a significant revenue share in the market. In the United States, the market was valued at USD 1.96 billion in 2023 and is expected to grow at a CAGR of 1.53% from 2024 to 2030. The growth is driven by the presence of major players in the region, including Amgen, GlaxoSmithKline, Novartis, Mireco, Pfizer, sydneymedic research & clinical trials company, Westwood & Waton, and Accord, which play key roles in driving growth.
The region studied by North America and Europe is defined as the United Kingdom, Germany, France, Italy, Luxembourg, the Irish republic, the New Zealand republic, the Middle States, the Netherlands, Spain, and the United States. The U. S. region holds a combined revenue share of over 30.8 million and is expected to grow at a CAGR of 2.3% from 2024 to 2030.
The Asia-Pacific region was valued at USD 2.28 billion in 2023 and is expected to grow at a CAGR of 2.4% from 2024 to 2030. The growth is attributed to a series of factors, including the integration of Novartis' Crestor treatment business in countries such as China, Japan, and India, as well as the expansion of Accord' business in countries such as China, India, and Singapore. The growth is also being driven by the growth of Accord' pharmaceutical business in countries like the Philippines, Singapore, and the Euro-zone.
The African region is driven by the presence of key players in the global Crestor market including Corex, Genentech, Aurobindo Pharma, J& J, and Teva. The expansion of Crestor in African regions is anticipated to continue, contributing to the growing demand for cholesterol management. The growth of Crestor is also driven by the presence of African regions' distinct strengths in cholesterol management.
The rise of statins, such as fibrates, has made statidout more accessible. Amgen, GlaxoSmithKline, and Novartis' statidout brands have received increased attention due to the increased incidence of cardiovascular events and hospitalizations in recent years. This increased accessibility has led to the growth of statins throughout the region, particularly in countries like the African and Asia-Pacific regions.
The increasing awareness of cardiovascular risks in countries like India and the Euro-zone has led to the development of cholesteryl alcohol- and statin-free diets. This diets contain high-fat foods that promote high cholesterol production and hence are more prone to side effects such as a high risk of heart attack and stroke.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$12.95
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Product DescriptionHealthylife is a pharmacist withchemistburySpoileryLauren Rose, PharmDHealthylife.au is a leading provider of product information, including product ratings and reviews, for Healthylife.au offers product information to make sure you are getting the information you want. This information is for guidance only. Healthylife.au does not recommend any product or course of treatment or medical advice. Always consult with your healthcare professional before starting or stopping any particular medication.Share Share Share Share Share Share Share Share Share Share Share Share Share Share Share ShareCopy FREE [email protected] has been providing free educational services via email. If you would like any additional information please contact bazaarvoice. Healthylife.au has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected] has not licensed [email protected].Pfizer Inc. said on Monday that it has entered into an agreement with AstraZeneca to sell Crestor for about $6 billion to treat high cholesterol.
The deal is expected to close by end the second quarter, when the company is expected to close its second-quarter earnings reports.
The company, based in New York, said the cash and cash equivalents at its New York, New Haven and Boston locations were $10.5 billion and $4.4 billion, respectively.
Pfizer said it had entered into the agreement with the AstraZeneca drug maker to reduce its share price of the drug from $10.2 billion to $10.6 billion.
The company has previously said it will use the agreement to promote Crestor sales at the high-growth companies in the United States.
In a statement, AstraZeneca said that the company “will not be making any changes in the future and will remain wholly owned and operated by AstraZeneca.”
The deal will close after the second quarter. AstraZeneca said it will continue to make and sell the drug, and will continue to market the drug.
Crestor sales increased by 17 percent to $10.5 billion, from a year earlier, the company said in a statement.“The success of our strategy and strategy for AstraZeneca’s cholesterol drug Crestor has been remarkable and our strategy has been to ensure that Crestor sales continue to grow at a sustainable rate,” AstraZeneca said in a statement.
Crestor is AstraZeneca’s top cholesterol drug, with sales of $12.7 billion in the first nine months of the year. It has been available at a price of $4.40 a tablet.
The drug’s maker, Pfizer Inc., has not disclosed its full financial results for the second quarter of this year. The company has also not commented on future financial results.
The drug’s sales were down 11 percent to $5.7 billion in the quarter, compared with $8.3 billion the second quarter of last year.
In a statement, AstraZeneca said, “The recent launches of Crestor and our commitment to the treatment of high cholesterol and other cardiovascular diseases is an example of our continued success in improving cardiovascular health for patients worldwide.”
The company added that the drug “has shown no evidence of sustained cardiovascular benefit in the long term, with some patients experiencing favorable long-term outcomes.”
The company also noted that sales of Crestor have been “generally modest” in the past year.
AstraZeneca said in a statement that it has “not had any financial reasons for the loss of sales of Crestor, and will continue to make all available available information” about the drug.
Crestor sales increased by 17 percent to $5.7 billion from a year earlier, the company said in a statement.The company said that it has been “encouraging” AstraZeneca to make a decision to move the drug from its New York, New Haven and Boston locations to a new facility in New Jersey, where it could be “better able to focus on the treatment of high cholesterol and other cardiovascular diseases.”
The company said that it will continue to make Crestor available at its New York, New Haven and Boston locations, including its New Jersey site, while making other available information about the drug.
In a statement, AstraZeneca said it will “continue to make changes to the way the company works,” including to “improve its ability to market and sell the drug.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$12.95
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
What is Crestor Rosuvastatin (5mg) used for: Rosuvastatin is a medication used to treat cholesterol and other fats in patients with familial hypercholesterolemia, high cholesterol, and other lipid levels. It is also used to lower LDL cholesterol levels and to treat familial hypercholesterolemia.What is the difference between Crestor Rosuvastatin (5mg) and Other Rosuvastatin (5mg)?Crestor Rosuvatin is a prescription only medication, effective for a minimum of 5 years, with a pharmacy benefit manager (PBM) as the sole judge. This medication is intended for use by patients with cholesterol levels of less than 300 mg/dl or those with more severe cholesterol levels, even if they have milder cholesterol levels. In cases of severe cholesterol levels, Crestor Rosuvatin may be required to be taken twice daily. In some cases, Crestor Rosuvatin may be prescribed for other indications, such as prevention of coronary heart disease or treatment of patients with familial hypercholesterolemia.
Supply Demandruck TimeDrogensolventcoastGastrointestinal (GIT) tract (abdomen) & liverWhat is the difference between Crestor Rosuvatin (5mg) and Other Rosuvatin (5mg)?This medication is intended for use by patients with cholesterol levels of less than 300 mg/dl or those with more severe cholesterol levels, even if they have mild cholesterol levels.
What is the difference between Crestor Rosuvatin (5mg) and Other Rosuvatin (5mg)Medicare CardNo MedicareGenericDrugsHealthylife Pharmacy, as the independent pharmacy company, offers a prescription only medicine (S4) product for purchase via this website.
Stade de France Pharmacy